Brain natriuretic peptide
Peer reviewed by Dr Doug McKechnie, MRCGPLast updated by Dr Philippa Vincent, MRCGPLast updated 7 May 2025
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Heart failure article more useful, or one of our other health articles.
Synonym: B-type natriuretic peptide
Background
Brain natriuretic peptide (BNP) levels increase markedly in left ventricular dysfunction and the level in heart failure correlates with symptom severity. BNP can therefore be an important clinical marker for the diagnosis of heart failure in patients with unexplained dyspnoea.
Other clinical applications, such as screening for asymptomatic ventricular dysfunction, establishing the prognosis or guiding the titration of drug therapy and prediction of future cardiovascular events, are under investigation but have not yet been sufficiently validated for widespread clinical use.1
BNP is a biologically active peptide of 32 amino acids and has vasodilator and natriuretic properties. BNP is cleaved from the 108-amino acid pro-brain natriuretic peptide released from the cardiac ventricles in response to stretching of the chamber.
The second remnant after cleavage, N-terminal pro-brain natriuretic peptide (NT-proBNP), is a 76-amino acid peptide with no known biological function which circulates at higher concentrations than BNP and may represent cardiac status over longer periods.2
The release of BNP appears to be in direct proportion to ventricular volume expansion and pressure overload. BNP increases with right or left systolic or diastolic heart failure. It is an independent predictor of high left ventricular end-diastolic pressure. BNP levels decrease after effective treatment of heart failure.
Until recently, BNP measurement was controversial as there was no clear evidence of the value of treating BNP levels, independent of symptoms.3 Recent studies have confirmed that treating BNP levels reduces morbidity and mortality.4The STRONG-HF study was stopped early due to the benefits seen in rapid up-titration of heart failure medication guided by BNP measurement.
BNP has been shown to be the single most accurate predictor of the absence of heart failure if the levels are below 100 nanomoles per litre.4
Measurement
BNP is mainly used in the assessment of patients with possible heart failure. The National Institute for Health and Care Excellence (NICE) recommends:5
Measure N-terminal pro-B-type natriuretic peptide (NT-proBNP) in people with suspected heart failure.
Because very high levels of NT-proBNP carry a poor prognosis, refer people with suspected heart failure and an NT-proBNP level above 2000 ng/litre (236 pmol/litre) urgently, to have specialist assessment and transthoracic echocardiography within two weeks.
Refer people with suspected heart failure and an NT-proBNP level between 400 and 2000 ng/litre (47 to 236 pmol/litre) to have specialist assessment and transthoracic echocardiography within six weeks.
An NT-proBNP level less than 400 ng/litre (47 pmol/litre) in an untreated person makes a diagnosis of heart failure less likely. The level of serum natriuretic peptide does not differentiate between heart failure with reduced ejection fraction and heart failure with preserved ejection fraction.
Review alternative causes for symptoms of heart failure in people with NT-proBNP levels below 400 ng/litre. If there is still concern that the symptoms might be related to heart failure, discuss with a heart failure specialist.
Potential causes of abnormal BNP levels5
High levels of serum natriuretic peptides can be associated with:
Age over 70 years.
Heart failure
Left ventricular hypertrophy.
Ischaemia.
Tachycardia.
Right ventricular overload.
Hypoxaemia (including pulmonary embolism).
Renal dysfunction (eGFR less than 60 ml/minute/1.73 m2).
Reduced levels of serum natriuretic peptides can occur with:
Obesity.
African or African-Caribbean family origin.
Treatment with diuretics, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, angiotensin II receptor blockers (ARBs) or mineralocorticoid receptor antagonists (MRAs).
Patient picks for Cardiovascular disease

Professional
Bickerstaff's brainstem encephalitis
This disease is notifiable in the UK - see NOIDs article for more details. Bickerstaff's brainstem encephalitis (BBE) is an immune disorder of unknown aetiology. It is characterised by: Acute, progressive cranial nerve dysfunction. Associated cerebellar ataxia. Coma. There is a clinical continuum between BBE and Fisher's syndrome Ito M, Kuwabara.
by Dr Roger Henderson, MBBS

Professional
Brain tumours in adults
See the separate Brain Tumours in Children Brain tumours in children article. Brain tumours cannot truly be differentiated into benign or malignant. Epidemiology Brain, other CNS and intracranial tumours statistics - UK incidence statistics; Cancer Research UK 19589 : Cancer Research UKBrain, other CNS and intracranial tumours statistics Primary.
by Dr Colin Tidy, MRCGP

Professional
Brain tumours in children
Brain tumours are the most common site for solid tumours in childhood. Pollack IF, Agnihotri S, Broniscer A; Childhood brain tumors: current management, biological insights, and ... J Neurosurg Pediatr. 2019 Mar 1;23(3):261-273. doi: 10.3171/2018.10.PEDS18377. 66981 : Childhood brain tumors: current management, biological insights, and future.
by Dr Colin Tidy, MRCGP

Professional
Space-occupying lesions of the brain
What is a space-occupying lesion of the brain. A space-occupying lesion of the brain is usually due to a tumour (53% of these in the UK are benign and 47% are malignant Brain Tumour Grades Brain Tumour Grades ) but it can be caused by other pathology such as an abscess or a haematoma. Generalis... Am Fam Physician. 2016 Feb 1;93(3):211-7. 57802 :.
by Dr Philippa Vincent, MRCGP

Medicine
Temozolomide for brain cancer
You will be prescribed temozolomide to take in 'cycles'. A cycle is a certain number of days where you take a dose of temozolomide, followed by a number of days without taking any doses. Your doctor will tell you how many capsules to take for each dose, and on which days to take them. You must take the capsules when your stomach is empty, which means taking them one hour before any food, or waiting until two hours afterwards. Your doctor will discuss with you the possibility of unwanted side-effects. You will have an increased risk of infection and bleeding, so it's important that you let your doctor know straightaway if you develop a high temperature (fever) or sore throat, or if you develop any unusual bleeding or bruising.
by Michael Stewart, MRPharmS
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
Further reading and references
- Ray SG; Natriuretic peptides in heart valve disease. Heart. 2006 Sep;92(9):1194-7. Epub 2005 Oct 26.
- Heart failure - chronic; NICE CKS, August 2024 (UK access only)
- Jankowski M; B-type natriuretic peptide for diagnosis and therapy. Recent Pat Cardiovasc Drug Discov. 2008 Jun;3(2):77-83.
- Hobbs FD, Davis RC, Roalfe AK, et al; Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ. 2002 Jun 22;324(7352):1498.
- Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society; Journal of Cardiac Failure
- Natriuretic Peptides in Clinical Practice: A Current Review; Lee and Aw; Journal of Immunological Sciences
- Chronic heart failure in adults - diagnosis and management; NICE Guidance (Sept 2018)
- Inflammation and Circulating Natriuretic Peptide Levels; H Fish-Trotter et al
- McKechnie DG, Papacosta AO, Lennon LT, et al; Inflammatory markers and incident heart failure in older men: the role of NT-proBNP. Biomark Med. 2021 Apr;15(6):413-425. doi: 10.2217/bmm-2020-0669. Epub 2021 Mar 12.
About the reviewerView full bio

Dr Doug McKechnie, MRCGP
Medical Writer
MA, MBBS, MSc, DRCOG, MRCP(UK), MRCGP(2021), FHEA
Dr Doug McKechnie is an NHS GP working in London. He works full-time clinically and is also the Deputy Lead for the Clinical and Professional Practice module at University College London Medical School.
More in cardiovascular disease
- Angiotensin-converting enzyme inhibitors
- Aortic regurgitation
- Axillary vein thrombosis
- Breathlessness
- Broad complex tachycardias
- Buerger's disease
- Cardiac tumours
- Carotid artery stenosis
- Chest pain
- Congenital heart disease in adults
- Cor pulmonale
- Coronary artery vasospasm
- Deep vein thrombosis
- Defibrillation and cardioversion
- Epidemiology of coronary heart disease
- Heart failure management
- Hyperlipidaemia
- Hypertension in pregnancy
- Thoracic aortic aneurysms


